Phase II trial of etoposide in APUD tumors

Cancer Treat Rep. 1987 Mar;71(3):305-7.

Abstract

Thirty-three patients with advanced, metastatic APUD tumors (islet cell, carcinoid, or medullary carcinomas of the thyroid) were treated with etoposide as a single agent. Of 29 evaluable patients, four (14%) had partial responses (95% confidence limits, 1%-26%). Toxic effects seen were those previously reported for etoposide as a single agent. Etoposide has activity in APUD tumors; further studies with this agent are indicated.

MeSH terms

  • Adenoma, Islet Cell / drug therapy*
  • Adult
  • Aged
  • Calcitonin / blood
  • Carcinoembryonic Antigen / analysis
  • Carcinoid Tumor / drug therapy*
  • Drug Evaluation
  • Etoposide / adverse effects
  • Etoposide / therapeutic use*
  • Female
  • Gastrins / blood
  • Humans
  • Hydroxyindoleacetic Acid / blood
  • Male
  • Middle Aged
  • Thyroid Neoplasms / drug therapy*

Substances

  • Carcinoembryonic Antigen
  • Gastrins
  • Hydroxyindoleacetic Acid
  • Etoposide
  • Calcitonin